Influenza Diagnostic Global Market Sees Growth Rate Of 8% Through 2022

14 Feb, 2022

The global influenza diagnostic market size is expected to grow from $1.75 billion in 2021 to $1.89 billion in 2022 at a compound annual growth rate (CAGR) of 8.4%. The change in the influenza diagnostic market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2021. The influenza diagnostic market is expected to reach $2.53 billion in 2026 at a CAGR of 7.6%.

What is the Global Influenza Diagnostic Market?

The influenza diagnostic market consists of sales of diagnostic tests used to diagnose influenza including viral culture, serology, rapid antigen testing, Reverse Transcription-Polymerase Chain Reaction (RT-PCR), immunofluorescence assays, and rapid molecular assays. Influenza, commonly known as flu, is a contagious illness caused by the influenza virus. Three varieties of this virus affect people: type A, type B, and type C. Common symptoms include fever, sore throat, cough, body ache, fatigue, and headache. The market consists of revenues generated by establishments conducting the diagnostics tests for influenza virus detection.

Get a Sample of the global influenza diagnostic market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3237&type=smp

What drives the Global Influenza Diagnostic Market?

The major factor driving the market is increasing funding for research on influenza diagnostics. Addressing the public health impact of influenza disease requires a proper understanding of the virus and its effect on individuals and populations. Therefore, it is important to accelerate the pace of scientific research progress that can have the greatest public health impact. Many public and private health organizations, researchers, health professionals, biopharmaceutical companies have maximized the spending for research funds or grants to reduce the risk of the emergence of pandemic influenza. For instance, in 2019, the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health, has initiated the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, a new network of research centers that will work together to develop influenza vaccines. NIAID will provide up to approximately $51 million in total first-year funding for the program, which is designed to support the CIVICs program centers over seven years.

Get the full global influenza diagnostic industry report here:

https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Global Influenza Diagnostic Market Segments
The global influenza diagnostic market is segmented:
By Traditional Diagnostic Tests: Rapid Influenza Diagnostic Tests (RIDT), Viral Culture, DFA, Serological Assays, Others
By Molecular Diagnostic Tests: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification Tests (INAAT), Loop Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Other Isothermal Nucleic Acid Amplification Tests, Others
By End User: Hospitals and Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Others
By Geography: The regions covered in the influenza diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Influenza Diagnostic Global Market Report 2022provides market size and growth forecasts for the global influenza diagnostic market, global influenza diagnostic market share, influenza diagnostic market segments and geographies, influenza diagnostic market competitive landscape including leading competitors’ revenues, profiles and market shares. The influenza diagnostic market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Global Influenza Diagnostic Industry Playersinclude F. Hoffmann-La Roche Ltd, Quidel Corporation, Abbott Laboratories, Hologic, Becton Dickinson and Company, DiaSorin S.p.A., Luminex Corporation, Meridian Bioscience Inc. and GenMark Diagnostics. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.